medigraphic.com
ISSN 1817-5996 (Electronic)

2014, Number 3

<< Back Next >>

Rev Cub de Reu 2014; 16 (3)

Behcet's disease

Castillo GW, González-Argote J, Hernández EJ

Language: Spanish
References: 84
Page: 309-321
PDF size: 658.47 Kb.


ABSTRACT

The Behçet's disease is a chronic inflammatory disease, recurrent, multisystem of unknown etiology. All events are self-limited except the ocular condition. It characterized by periods of exacerbation remission and unpredictable frequency and duration. Is based the diagnosis is based on the association of especially bipolar aphthosis, skin manifestations, uveitis and affectation of great vessels. In the absence of these signs is more difficult to confirm the diagnosis. The lesions of the gastrointestinal tract and central nervous system is less frequent, even so may threaten the patient's life. The susceptibility of Behçet´s disease is strongly associated with the presence of HILA -B51 allele. The neurological manifestations are signs of malignancy.


REFERENCES

  1. Collazo Borrego L, Soto Escobar A, Averhoff Casamayor MC, Turcaz Bosh N, Ramos Sánchez V, Torres Escalonas N. Síndrome de Behcet. Reporte del primer caso en Cuba. Rev Cubana Estomatol. 1989;26(3):175-80.

  2. Mutlu S, Scully C. The person behind the eponym: Hulûsi Behçet (1889-1948). J Oral Pathol Med. 1994;23(7):289-96.

  3. Tunc R, Uluhan, A, Melikoglu M, Ozyazgan Y, Ozdogan H, Yazici H. A reassessment of the International Study Group criteria for the diagnosis (classification) of Behçet's syndrome. Clinical and experimental rheumatology. 2001;19(5 Suppl 24):S45.

  4. Yazici H, Yazici Y. Behçet's syndrome. London: Ed. Springer; 2010. p. 231-38.

  5. O'Neill, TW, Rigby AS, Silman AJ, Barnes C. Validation of the International Study Group criteria for Behçet's disease. Rheumatology. 1994;33(2):115-7.

  6. International Team for the Revisin of the Internacional Criteria for Behçet's Disease (ITR-ICBD). Revision of the International Criteria for Behçet's Disease (ICBD). Clin Exp Rheumatol. 2006;24 Suppl 42:S14-5.

  7. Ginarte M, Toribio J. Síndrome de Sweet. Medicina clínica. 2009;133(1):31-5.

  8. Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen J. Epidemiology of Behcets disease. Ocul Immunol Inflamm. 2012;20(5):324-35.

  9. Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002;33(2):95-106.

  10. Carreño Pérez L. Enfermedad de Behçet. An. Med. Interna [revista en Internet]. 2001 Ago [citado 18 abril 2014];18(8):5-10. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992001000800001&lng=es

  11. Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, Yazici H. The pustular skin lesions in Behcet’s syndrome are not sterile. Annals of the rheumatic diseases. 2004;63(11):1450-2.

  12. Ozen S. Familial Mediterranean fever: revisiting an ancient disease. European journal of pediatrics. 2003;162(7-8):449-54.

  13. Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Abdollahi BS. Behcet’s disease: from East to West. Clinical rheumatology. 2010;29(8):823-33.

  14. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams,H. Ocular features of Behçet’s disease: an international collaborative study. British Journal of Ophthalmology. 2007;91(12):1579-82.

  15. López de Maturana LD, Amaro BP, Balestrini DC, Segovia GL. Manifestaciones clínicas en 5 casos de enfermedad de Behçet: Report of 5 cases. Rev. méd. Chile [revista en Internet]. 2002 Mayo [citado 12 mayo 2014];130(5):551-56. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872002000500010&lng=es&nrm=iso&tlng=es

  16. Hernández GAM, Sanabria CR.). Enfermedad de Behcet. Revista medica de costa rica y Centroamérica. 2014;71(611):523-8.

  17. Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves, O, Valente J. Behçet's disease a contemporary review. Journal of autoimmunity. 2009;32(3):178-88.

  18. Yazici H, Fresko I, Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nature Clinical Practice Rheumatology. 2007;3(3):148-55.

  19. Seyahi E, Melikoglu M, Yazici H. Clinical features and diagnosis of Behcet's syndrome. Int J Adv Rheumatol. 2007;5(1):8-11.

  20. Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Yazici H. A double-blind trial of depot corticosteroids in Behcet's syndrome. Rheumatology. 2006;45(3):348-52.

  21. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: com pathways with other diseases. Gut. 2011;60(12):1739-53.

  22. Saadoun D, Wechsler B, Resche‐Rigon M, Trad S, Le Thi Huong D, Sbai A, Piette JC. Cerebral venous thrombosis in Behçet's disease. Arthritis Care & Research. 2009;61(4):518-26.

  23. Alpsoy E, Zouboulis C, Ehrlich GE. Mucocutaneous lesions of Behçet's disease. Yonsei medical journal. 2007;48(4),573-85.

  24. Yi SW, Cheon JH, Kim JH, Lee SK, Kim TI, Lee YC, Kim WH. The prevalence and clinical characteristics of esophageal involvement in patients with Behçet's disease: a single center experience in Korea. Journal of Korean medical science. 2009;24(1):52-6.

  25. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M.. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-78.

  26. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Solinger A. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Annals of the rheumatic diseases. 2012;71(4):563-6.

  27. Bañares A, Pato E, Abasolo L. Treatment of refractory posterior uveítis with anti-TNF alfa (Infliximab). Ann Rheum. Dis. 2001;60 Suppl 1:S145-9.

  28. Sarica-Kucukoglu R, Akdag-Kose A, Kayabal IM, Yazganoglu KD, Disci R, Erzengin D, Azizlerli G. Vascular involvement in Behçet's disease: a retrospective analysis of 2319 cases. Int J Dermatol. 2006;45(8):919-21.

  29. Paller AS, Mancini AJ. Hurwitz clinical pediatric dermatology: a textbook of skin disorders of childhood and adolescence. Chapter 25. New York: Ed. Elsevier Health Sciences; 2011.

  30. Seyahi E, Melikoglu M, Akman C, Hamuryudan V, Ozer H, Hatemi G, Yazici H. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine. 2012;91(1):35-48.

  31. Caramaschi P, Poli G, Bonora A, Volpe A, Tinazzi I, Pieropan S, Biasi D. A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine. 2010;77(4):330-4.

  32. Ramos-Casals M, Diaz C, Cuadrado MJ, Khamashta, M A. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmunity reviews. 2010;9(3):188-93.

  33. Branch DW, EllerAG. Antiphospholipid syndrome and thrombosis. Clinical obstetrics and gynecology. 2006;49(4):861-74.

  34. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. American journal of ophthalmology. 2008;146(6):845-50.

  35. Saadoun D, Bodaghi B, Bienvenu B, Wechsler B, Sene D, Trad S, Sève P. Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. Autoimmunity reviews. 2013;12(7):774-83.

  36. Al-Araji A, & Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. The Lancet Neurology. 2009;8(2):192-204.

  37. Salas Cabrera R, Sagué Larrea J, Laurencio Mena A. Enfermedad de Behcet: Presentación de un caso. Arch. Esp. Urol. [revista en Internet]. 2007 Feb [citado 19 noviembre 2013];60(1):67-8. Disponible en: http://scielo.isciii.es/pdf/urol/v60n1/caso1.pdf

  38. Sumida T, Tsuboi H, Iizuka M, Nakamura Y, Matsumoto I. Functional role of M3 muscarinic acetylcholine receptor (M3R) reactive T cells and anti-M3R autoantibodies in patients with Sjögren's syndrome. Autoimm. reviews. 2010;9(9):615-7.

  39. Gotkine M, Vaknin-Dembinsky A. Central nervous system vasculitis. Current treatment options in neurology. 2013;15(3):367-74.

  40. Hatemi G , Silman A, Bang , Bodaghi B, Chamberlain AM, Gul A, Yazici H. EULAR recommendations for the management of Behçet disease. Annals of the rheumatic diseases. 2008;67(12):1656-62.

  41. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. In Seminars in arthritis and rheumatism. 2011;(41(1):61-70.

  42. Mathews SA, Kurien BT, Scofield RH. Oral manifestations of Sjögren's syndrome. J Dent Res. 2008;87(4):308-18.

  43. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol. 2010;6(9):529-37.

  44. Ebert EC. Gastrointestinal manifestations of Behçet’s disease. Digestive diseases and sciences. 2009;54(2):201-07.

  45. Millán Parrilla F, Quecedo Estébanez E, Gimeno Carpio E. Tratamiento de la estomatitis aftosa recidivante. Piel. 2010;25(8):463-9.

  46. Mutinga ML, Odze RD, Wang H H, Hornick JL, Farraye, FA. The clinical significance of right‐sided colonic inflammation in patients with left‐sided chronic ulcerative colitis. Inflammatory bowel diseases. 2004;10(3):215-9.

  47. Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon α in Behçet disease: review of the literature. In Seminars in arthritis and rheumatism. 2004;33(5):320-35.

  48. Mizuki N, Meguro A, Tohnai I, Gül A, Ohno S, Mizuki N. Association of major histocompatibility complex class I chain- related gene A and HLA-B alleles with Behçet's disease in Turkey. Japanese journal of ophthalmology. 2007;51(6):431-6.

  49. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Survey of ophthalm. 2005;50(4):297-350.

  50. Pozo González A, Barbán Fernández L, Rodríguez del Valle KM, Betancourt Fernández I. Síndrome de Behçet: presentación de un caso. AMC [revista en Internet]. 2010 Dic [citado 5 Septiembre 2014];14(6):1-7. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552010000600016&lng=es

  51. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M. Adalimumab in the therapy of uveitis in childhood. British Journal of Ophthalmology. 2007;91(3):319-24.

  52. Yılmaz S, Cimen KA. Pulmonary artery aneurysms in Behçet’s disease. Rheumatology international. 2010;30(10):1401-3.

  53. Martínez Larrarte JP, Cepero Morales R, Sosa Almeida M, Molinero Rodríguez C, Lantigua Martell MA. Síndrome de Behcet: Presentación de un caso. Rev cubana med [revista en Internet]. 1998 Dic [citado 23 marzo 2014];7(4):249-52. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75231998000400007&lng=es

  54. Toro A, Pinto L, Velásquez C, Márquez J. Enfermedad de Behcet. Revista Colombiana de Reumatología. 2009;16(1):97-111.

  55. Jennette1 JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism. 2013;65(1):1-11.

  56. Wurmann Pamela, Díaz Gonzalo, Sabugo Francisca, Soto Lilian, Solanes Federica, Pino Sandra et al. Retrospective review of 44: Chilean patients with Behçet disease. Rev. méd. Chile [revista en Internet]. 2009 Oct [citado 23 marzo 2014];137(10):1333-40. Disponible en: http://www.scielo.cl/scielo.php?pid=S0034-98872009001000008&script=sci_arttext&tlng=en

  57. Ozkan F, Cetin GY, Bakan B, Kalender A, Yuksel M, Ekerbicer HC, Sayarlioglu M. Sonographic Evaluation of Subclinical Entheseal Involvement in Patients With Behçet Disease. American Journal of Roentgenology. 2012;199(6):723-9.

  58. Bayetto K, Logan RM. Sjögren's syndrome: a review of aetiology, pathogenesis, diagnosis and management. Aust Dent J. 2010;55 Suppl 1:39-47.

  59. Beers Mark H, Porter Robert S. Manual de Merck. En: Schumacher Ralph H, Enfermedades difusas del tejido conjuntivo: Síndrome de Behcet. Madrid: Ed. Elsevier; 2006. p. 294-6

  60. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario, F, Watts RA. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis & Rheumatism. 2013;65(1):1-11.

  61. Fonseca A, Rocha-Filho P, Melo A. Neuro-Behçet: differential diagnosis of recurrent meningitis. Rev Med Chile. 2013;141:114-8.

  62. Saldarriaga-Rivera L, da-Silveira-Campos G, Delgado-Quiroz L, Rios-Gomes-Bica B. Síndrome de la vena cava en paciente con Enfermedad de Behçet. Revista Cubana de Reumatología [revista en Internet]. 2014 [citado 15 julio 2014];16(2):[aprox. 4 p.]. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/283

  63. Rodés Teixidor J, Guardia Massó J. Tratado de Medicina Interna. En: Vázquez Rodríguez JJ, Peña Sánchez de Rivera JM, editores. Otras 9 Enf. inflamatorias sistémicas de etiología desconocida. Barcelona: Ed. Masson SA; 2006. p. 3250-2

  64. Leiba L, Seligsohn V, Sidi Y, Harats D, Sela B, Griffin J, et al. Thrombophilic factors in not leading cause of thrombosis of Behcet’s disease. Ann Rheum Dis. 2004;63:1445-9.

  65. Hwang I, Lee CK, Yoo B, Lee I. Necrotizing villitis and decidual vasculitis in the placentas of mothers with Behçet disease. Human pathology. 2009;40(1):135-38.

  66. Jadaon J, Shushan A, Ezra Y, Sela H Y, Ozcan C, Rojansky N. Behçet's disease and pregnancy. Acta obstetricia et gynecologica Scandinavica. 2005;84(10):939-44.

  67. Grigg E, Kane S, Katz S. Mimicry and Deception in Inflammatory Bowel Disease and Intestinal Behçet Disease. Gastroenterology & Hepatology. 2012;8(2):103-9

  68. Direskeneli H. Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? Rheumatology. 2006;45(12):1461-5.

  69. Birtas-Atesoglu E, Inanc N, Yavuz S, Ergun T, Direskeneli H. Serum levels of free heat shock protein 70 and anti-HSP70 are elevated in Behcet's disease. Clinical & Experimental Rheumatology. 2008;26(4):S96.

  70. Mora Hernández GA, Ríos Sanabria C. Enfermedad de Behcet. Revista medica de costa rica y Centroamérica. 2014;LXXI(611):523-8.

  71. Pila Pérez RV, Pila Peláez RU, Rosales Torres P, Artola González JA. Enfermedad de Behcet: presentación de un caso. AMC [revista en Internet]. 2014 Feb [citado 18 julio 2014];18(1):134-45. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552014000100014&lng=es

  72. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nature Reviews Immunology. 2006;6(11):823-35.

  73. Mahammad A, Mandl T, Stufeet C, Segel Mark M. Incidence, prevalence and clinical characteristics of Behcet’s disease in southern Sweden. Rheumatology(Oxford). 2013;52(2):304-10.

  74. García-Palenzuelaa R, Graña J, Varela M, Tovar M. Actualización de la enfermedad de Behcet. A propósito de 2 casos en atención primaria. Semergen. 2012;38(1):33-9.

  75. Álvarez Álvarez G, Martínez Delgado F, González Cortiñas Mo, Martín García CL, Martínez Fraga A. Enfermedad de Behcet: Informe de 5 casos. Rev cubana med [revista en Internet]. 1998 Jun [citado 7 marzo 2014];37(2):119-22. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75231998000200009&lng=es

  76. Vandaele P, Kappen J, Van Hagen P, Van Laar J. Managing Behcet’s disease, an update on current and emerging therapies. Ther Clin Res Manag. 2009;5:385-90.

  77. Cruz Santana AN, Antunes T, Monteiro de Barros J, Adib Kairalla R, Ribeiro de Carvalho CR, Valente Barbas CS. Acometimento pulmonar na doença de Behçet: uma boa experiência com o uso de imunossupressores. J bras pneumol [serie en Internet]. 2008 [citado 18 abril 2014];34(6):[aprox. 9 p.]. Disponible en: http://www.scielo.br/scielo.php?pid=S1806-37132008000600005&script=sci_arttext&tlng=pt

  78. Marques Zaghetto JP, Mina Yamamoto M, Barreto Souza M, Bezerra Gaspar Carvalho da Silva FT, Hirata CE, Olivalves E, et al. Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis – a retrospective study. Arq Bras Oftalmol [serie en Internet] 2010 [citado 18 abril 2014]; 73(1):[aprox. 11 p.]. Disponible en: http://www.scielo.br/scielo.php?pid=S0004-27492010000100007&script=sci_arttext&tlng=es

  79. Sfikakis P, Markomichelakis N, Alpsoy E, Assad Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behcet is disease: Review and basis recommendations. Rheumatology. 2007;46(5):136-41.

  80. Santos A. Botequio L, Ribeiro E, Botega J. Alterações psiquiátricas após corticoterapia em paciente com rara manifestação neurológica de Síndrome de Behçet e o papel da interconsulta psiquiátrica. Rev Psiq Clín. 2009;36(5):203-5.

  81. Vidaller Palacín A, Robert Olalla J, Sanuy Jiménez B, Rufi Rigau G, Folch Civit J, Charte González A. Tratamiento de la enfermedad de Behçet. An. Med. Interna. 2002;19(11):52-6.

  82. Karakaya K, Comert M, Numanoglu G. Multiple perforations along the transverse colon as a rare presentation of intestinal behcet's disease: a case report. Clinics [serie en Internet]. 2009 [citado 12 mayo 2014];64(12):[aprox. 6 p.]. Disponible en: http://www.scielo.br/scielo.php?pid=S1807-59322009001200016&script=sci_arttext

  83. Balaguer J, Tarancón B, Novo E, García S. Afectación pericárdica en enfermedades de patogenia inmunológica, infecciosa y endocrinológicas. Medicine-Programa de Formación Médica Continuada Acreditado. 2013;11(43):2583-90.

  84. Harrison Online [homepage on the internet]. EEUU: Síndrome de Behçet; c1995-2010[actualizado 9 abril 2010; [citado 18 de abril de 2014]. Harrisonmedicina [aprox. 2 pantallas]. Disponible en: http://www.harrisonmedicina.com/content.aspx?aID=3743565&searchStr=s%c3%adSindrome+de+beh%c3%a7et#3743565




2020     |     www.medigraphic.com